Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clal, Teva deal

TEVA and CBI's Andromeda Biotech Ltd. subsidiary will partner to develop and commercialize Andromeda's DiaPep277, pending satisfactory interim results from a Phase III trial to treat Type I diabetes. Teva and undisclosed investors will finance the rest of development,

Read the full 396 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers